                               SEQUENCE LISTING

<110> BIOGEN IDEC MA INC.
 
<120> TWEAK ANTAGONISTS FOR TREATING LUPUS NEPHRITIS AND MUSCLE
      ATROPHY

<130> 13751-0212WO1

<140> PCT/US2014/059007
<141> 2014-10-03

<150> 61/887,209
<151> 2013-10-04

<160> 22    

<170> PatentIn version 3.5

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 1
Gly Phe Thr Phe Ser Arg Tyr Ala Met Ser 
1               5                   10  


<210> 2
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 2
Glu Ile Ser Ser Gly Gly Ser Tyr Pro Tyr Tyr Pro Asp Thr Val Thr 
1               5                   10                  15      


Gly 
    


<210> 3
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 3
Val Leu Tyr Tyr Asp Tyr Asp Gly Asp Arg Ile Glu Val Met Asp Tyr 
1               5                   10                  15      


<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Phe"

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Thr"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Thr" or "Asp" or "Asn"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Tyr"

<220>
<221> VARIANT
<222> (9)..(9)
<223> /replace="Ile" or "Leu"

<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Ser"

<220>
<221> misc_feature
<222> (1)..(10)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 4
Gly Tyr Asn Phe Ser Arg Tyr Ala Met His 
1               5                   10  


<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Val"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Ser"

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Lys"

<220>
<221> misc_feature
<222> (1)..(8)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 5
Tyr Tyr Pro Asp Thr Val Thr Gly 
1               5               


<210> 6
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Leu"

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Leu"

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Phe"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Phe"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Phe"

<220>
<221> misc_feature
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 6
Val Ile Tyr Tyr Asp Tyr Asp 
1               5           


<210> 7
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Leu" or "Val" or "Met"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Gln" or "Asp"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Ala" or "Leu"

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Glu"

<220>
<221> misc_feature
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 7
Asp Arg Ile Glu Val Met Asp 
1               5           


<210> 8
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 8
Arg Ser Ser Gln Ser Leu Val Ser Ser Lys Gly Asn Thr Tyr Leu His 
1               5                   10                  15      


<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 9
Lys Val Ser Asn Arg Phe Ser 
1               5           


<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"

<400> 10
Ser Gln Ser Thr His Phe Pro Arg Thr 
1               5                   


<210> 11
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ile"

<220>
<221> VARIANT
<222> (7)..(7)
<223> /replace="Val"

<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Asn"

<220>
<221> VARIANT
<222> (16)..(16)
<223> /replace="His" or "Asp" or "Asn" or "Gln" or "Tyr"

<220>
<221> misc_feature
<222> (1)..(16)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 11
Arg Ser Ser Gln Ser Leu Lys Ser Ser Lys Gly Asn Thr Tyr Leu Glu 
1               5                   10                  15      


<210> 12
<211> 16
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Lys"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ile"

<220>
<221> VARIANT
<222> (10)..(10)
<223> /replace="Arg"

<220>
<221> VARIANT
<222> (13)..(13)
<223> /replace="Asn"

<220>
<221> misc_feature
<222> (1)..(16)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 12
Arg Ser Ser Gln Ser Leu Val Ser Ser Lys Gly Asn Thr Tyr Leu His 
1               5                   10                  15      


<210> 13
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Glu"

<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Val" or "Ile"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Tyr" or "Ser" 

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Trp"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ala" or "Asp"

<220>
<221> misc_feature
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 13
Lys Leu Ser Asn Arg Phe Ser 
1               5           


<210> 14
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (2)..(2)
<223> /replace="Leu" or "Val" or "Ile"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Tyr" or "Ser"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Ala" or "Asp"

<220>
<221> misc_feature
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 14
Lys Leu Ser Asn Arg Phe Ser 
1               5           


<210> 15
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (1)..(1)
<223> /replace="Met"

<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Ser" or "Ala"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Thr"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Glu" or "Gln"

<220>
<221> VARIANT
<222> (6)..(6)
<223> /replace="Trp" or "Leu"

<220>
<221> misc_feature
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 15
Ser Gln Gly Ser His Phe Pro 
1               5           


<210> 16
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      peptide"


<220>
<221> VARIANT
<222> (3)..(3)
<223> /replace="Ser" or "Ala"

<220>
<221> VARIANT
<222> (4)..(4)
<223> /replace="Ile" or "Thr"

<220>
<221> VARIANT
<222> (5)..(5)
<223> /replace="Glu" or "Gln"

<220>
<221> misc_feature
<222> (1)..(7)
<223> /note="Variant residues given in the sequence have no 
      preference with respect to those in the annotations
      for variant positions"

<400> 16
Ser Gln Gly Ser His Phe Pro 
1               5           


<210> 17
<211> 125
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 17
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Ser Ser Gly Gly Ser Tyr Pro Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Leu Tyr Tyr Asp Tyr Asp Gly Asp Arg Ile Glu Val Met 
            100                 105                 110         


Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120                 125 


<210> 18
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 18
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Ser Ser 
            20                  25                  30          


Lys Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Phe Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210> 19
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 19
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Ser Ser 
            20                  25                  30          


Lys Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser 
                85                  90                  95      


Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


<210> 20
<211> 454
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 20
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Tyr 
            20                  25                  30          


Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Glu Ile Ser Ser Gly Gly Ser Tyr Pro Tyr Tyr Pro Asp Thr Val 
    50                  55                  60                  


Thr Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Val Leu Tyr Tyr Asp Tyr Asp Gly Asp Arg Ile Glu Val Met 
            100                 105                 110         


Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 
        115                 120                 125             


Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser 
    130                 135                 140                 


Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 
145                 150                 155                 160 


Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 
                165                 170                 175     


Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 
            180                 185                 190         


Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys 
        195                 200                 205             


Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu 
    210                 215                 220                 


Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 
225                 230                 235                 240 


Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 
                245                 250                 255     


Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 
            260                 265                 270         


Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 
        275                 280                 285             


Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 
    290                 295                 300                 


Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 
305                 310                 315                 320 


Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 
                325                 330                 335     


Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 
            340                 345                 350         


Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 
        355                 360                 365             


Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 
    370                 375                 380                 


Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 
385                 390                 395                 400 


Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 
                405                 410                 415     


Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 
            420                 425                 430         


Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 
        435                 440                 445             


Leu Ser Leu Ser Pro Gly 
    450                 


<210> 21
<211> 219
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 21
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Ser Ser 
            20                  25                  30          


Lys Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Phe Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Phe Cys Ser Gln Ser 
                85                  90                  95      


Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
        115                 120                 125             


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
    130                 135                 140                 


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
145                 150                 155                 160 


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
                165                 170                 175     


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
            180                 185                 190         


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
        195                 200                 205             


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215                 


<210> 22
<211> 219
<212> PRT
<213> Artificial Sequence

<220>
<221> source
<223> /note="Description of Artificial Sequence: Synthetic
      polypeptide"

<400> 22
Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 
1               5                   10                  15      


Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Ser Ser 
            20                  25                  30          


Lys Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser 
        35                  40                  45              


Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 
    50                  55                  60                  


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 
65                  70                  75                  80  


Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Ser 
                85                  90                  95      


Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105                 110         


Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 
        115                 120                 125             


Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 
    130                 135                 140                 


Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 
145                 150                 155                 160 


Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 
                165                 170                 175     


Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 
            180                 185                 190         


Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 
        195                 200                 205             


Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 
    210                 215                 


